Exelixis shopping mall

Last week, Bristol-Myers Squibb Co. continued its decade-long collaboration with Exelixis Inc., acquiring rights to develop and commercialize two classes of preclinical compounds for metabolic and inflammatory diseases. In the former area, BMS gains compounds against a new target that could be combined with the pharma's DPP-4 antagonists to treat Type II diabetes.

In the latter, BMS gains compounds that target a T cell-mediated pathway central to many inflammatory and autoimmune disorders, an area that BMS has long focused on...